Location History:
- Hidaka, JP (1998 - 2002)
- Tokyo, JP (2019)
- Tokushima, JP (1996 - 2023)
Company Filing History:
7 out of 318 
1 out of 1 Years Active: 1996-2023
Title: Norihiko Suzuki: Innovator in Cancer Treatment
Introduction
Norihiko Suzuki is a prominent inventor based in Hidaka, Japan. He has made significant contributions to the field of cancer treatment, focusing on developing innovative methods that minimize side effects while maximizing therapeutic efficacy. With a total of 7 patents to his name, Suzuki's work is paving the way for advancements in oncology.
Latest Patents
Among his latest patents is an anti-tumor agent containing an immunomodulator and an antitumor effect potentiator. This novel cancer treatment method is designed to provide remarkable antitumor effects with fewer side effects. The invention utilizes a combination of a DNA function inhibitor and an immunomodulator to enhance treatment outcomes. Another significant patent addresses the alleviation of side effects caused by anti-tumor agents. This agent contains 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione or its pharmaceutically acceptable salt. It exhibits an inflammatory-suppressing action in the digestive tract, effectively alleviating diarrhea and weight loss associated with cancer treatments without compromising the anti-tumor effect.
Career Highlights
Norihiko Suzuki has worked with notable companies in the pharmaceutical industry, including Taiho Pharmaceutical Company Limited and Kotai Kasei Co., Ltd. His experience in these organizations has contributed to his expertise in developing effective cancer therapies.
Collaborations
Throughout his career, Suzuki has collaborated with esteemed colleagues such as Masakazu Fukushima and Shingo Yano. These partnerships have fostered a collaborative environment that enhances innovation and research in cancer treatment.
Conclusion
Norihiko Suzuki's contributions to cancer treatment through his innovative patents demonstrate his commitment to improving patient outcomes. His work not only addresses the efficacy of cancer therapies but also prioritizes the well-being of patients by minimizing side effects.